Exciting Developments from AusperBio at AASLD 2024
AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio) are making headlines with their innovative clinical-stage work. This promising biotechnology company is set to present groundbreaking clinical data regarding their lead candidate, AHB-137. This antisense oligonucleotide (ASO) therapeutic aims to provide a functional cure for chronic hepatitis B.
Key Details on the Upcoming Presentation
The much-anticipated presentation will be delivered at the renowned Liver Meeting, organized by the American Association for the Study of Liver Diseases (AASLD). This significant event is scheduled for mid-November and will bring together experts in the field to discuss advancements in liver disease treatment.
AHB-137’s oral presentation will focus on new findings that underline its potential impact on treatment outcomes for patients suffering from chronic hepatitis B. The details of the presentation are as follows:
Presentation Information
Title: HBsAg loss and seroconversion in HBeAg-negative chronic hepatitis B subjects on NA therapy after AHB-137 treatment: preliminary data from an ongoing multicenter, randomized, open-label phase IIa study.
Session: Late Breaking Abstract Parallel Session 2
Session Time: November 18, 2024, from 5:00 PM to 6:30 PM PDT
Presentation Time: November 18, 2024, from 6:00 PM to 6:15 PM PDT
Authors: The research team, including Yanhua Ding and others, will present the findings which are pivotal for understanding the therapeutic efficacy and potential of AHB-137.
Understanding AHB-137 and Its Mechanisms
AHB-137 is an innovative unconjugated antisense oligonucleotide developed through AusperBio's proprietary Med-Oligo™ ASO technology platform. This specialized platform is designed to treat chronic hepatitis B with an aim to achieve a functional cure. The company has showcased AHB-137's impressive preclinical and Phase 1 clinical data, drawing interest from the scientific community.
The therapy exemplifies a dual-mechanism action that targets the virus in unique ways, setting it apart from other treatments currently available. Presently, AHB-137 is advancing through a Phase 1b trial across multiple international locations and a concurrent Phase 2 trial, with a view towards a global solution for hepatitis B treatment.
About AusperBio and Its Mission
AusperBio is dedicated to transforming the landscape of biomedical technologies, focusing on oligonucleotide therapies and their associated delivery mechanisms. The company, with operations in the USA and other countries, strives to innovate in the realm of chronic illness treatment.
With the Med-Oligo™ ASO platform, AusperBio is not only refining ASO therapeutic designs but also enabling targeted delivery systems that significantly enhance treatment capabilities, making them more effective against a variety of conditions. Their commitment centers on combatting chronic hepatitis B, which remains a critical health challenge worldwide.
Frequently Asked Questions
What is AHB-137?
AHB-137 is an antisense oligonucleotide therapeutic designed to treat chronic hepatitis B, aiming for a functional cure.
When will the AHB-137 presentation take place?
The presentation is scheduled for November 18, 2024, at the Liver Meeting hosted by AASLD.
What are the expected outcomes of the presentation?
The presentation will discuss clinical trial results, including data showcasing HBsAg loss and seroconversion among participants.
What is AusperBio's focus?
AusperBio aims to advance oligonucleotide therapies, particularly for chronic hepatitis B, through innovative research and technology.
Where can I find more information about AusperBio?
For additional information about the company and its projects, please visit the AusperBio website.
